Azur Pharma Limited Revenue and Competitors

Azur Pharma is a private pharmaceutical company focused on the CNS, women's health and urology markets of the US. The company is headquartered in Dublin, Ireland. Azur Pharma markets a portfolio of prescription products through its US national sales infrastructure consisting of two specialty sales forces, one a CNS force and the other a women's health / urology force. Azur Pharma's portfolio comprises of CNS products including FazaClo®, women's health and urology products including Elestrin™, and an orphan disease product, Gastrocom®. FazaClo is an antipsychotic drug indicated for the management of severely ill schizophrenic patients who fail to respond to standard treatments. FazaClo also is indicated for reduction in the risk of recurrent suicidal behaviour in schizophrenia or schizoaffective disorders. Elestrin is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. Gastrocrom is indicated for the management of patients with mastocytosis. Azur Pharma's mission is to build an integrated pharmaceutical company focussed on the areas of CNS, women's health and urology. Azur Pharma's strategy is to acquire marketed products and late stage development opportunities in our target markets to leverage the specialist sales forces we have developed for these markets. The company was founded in May 2005 with a private equity funding of €40 million ($60 million). Since that time, Azur Pharma has acquired Gastrocrom, Niravam® and Parcopa® from UCB Pharma, Pharmelle a women's health and urology business, FazaClo from Avanir Pharmaceuticals and Elestrin from BioSante. Azur Pharma also completed an additional €35 million ($50 million) equity financing in August 2007. We invite you to explore our web site and learn more about Azur Pharma.